Morton Coleman

Morton Coleman

Auto-generated profile, based on publicly available information

Morton Coleman

Weill Cornell Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
RFRichard I. Fisher
Richard I. Fisher
MKMark S. Kaminski
Mark S. Kaminski
RWRichard Wahl
Richard Wahl
SKSusan J. Knox
Susan J. Knox
AZAndrew D. Zelenetz
Andrew D. Zelenetz
MCMorton Coleman
Morton Coleman
Purpose This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refractory low-grade, follicular, or transformed low-grade non-Hodgkin’s lymphoma (NHL) that resulted in the regulatory approval of the iodine-131 tositumomab by the US Food and Drug Administration. Patients and Methods This integrated analysis included 250 patients. Patients received a single course of iodine-131 tositumomab. Responses were assessed by an independent panel of radiologists and oncologists. Results Response rates in the five trials ranged from 47% to 68%; complete response rates ranged from 20% to 38%. With a median follow-up of 5.3 years, the 5-year progression-free survival was 17%. Eighty-one (32%) of 250 patients had a time to progression of ≥ 1 year (termed durable response population). For the durable response population, 44% had not progressed at ≥ 2.5 to ≥ 9.5 years and had a median duration of response of 45.8 months. The median duration of complete response was not reached. The durable response population had many poor prognostic characteristics, including bone marrow involvement (41%), bulky disease ≥ 5 cm (49%), and transformed histology (23%). Forty-three percent of the patients had been treated with more than four prior therapies and 36% had not responded to their most recent therapy. Conclusion The tositumomab and iodine-131 tositumomab therapeutic regimen produces high response rates in patients with relapsed or refractory low-grade, follicular, and transformed low-grade NHL, with a sizable subgroup of patients achieving long-term durable responses.

23 November 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
ANAriela Noy
Ariela Noy
SVSven de Vos
Sven de Vos
MCMorton Coleman
Morton Coleman
PMPeter Martin
Peter Martin
CFChristopher R. Flowers
Christopher R. Flowers
RCRobert Chen
Robert Chen
Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractory MZL treated with prior rituximab (RTX) or rituximab-based chemoimmunotherapy (RTX-CIT). We report the final analysis of PCYC-1121 with median follow-up of 33.1 months (range: 1.4-44.6). Overall response rate (ORR) was 58%; median duration of response (DOR) was 27.6 months (95% confidence interval [CI]: 12.1 to not estimable [NE]); median progression-free survival (PFS) was 15.7 months (95% CI: 12.2-30.4); and median overall survival (OS) was not reached (95% CI: NE to NE). Patients with prior RTX treatment had better outcomes (ORR: 81%; median DOR: not reached [95% CI: 12.2 to NE]; median PFS: 30.4 months [95% CI: 22.1 to NE]; median OS: not reached [95% CI: 30.3 to NE]) vs those with prior RTX-CIT treatment (ORR: 51%; DOR: 12.4 months [95% CI: 2.8 to NE]; PFS: 13.8 months [95% CI: 8.3-22.5]; OS: not reached [95% CI: NE to NE]). ORRs were 63%, 47%, and 62% for extranodal, nodal, and splenic subtypes, respectively. With up to 45 months of ibrutinib treatment, the safety profile remained consistent with prior reports. The most common grade ≥3 event was anemia (16%). Exploratory biomarker analysis showed NF-κB pathway gene mutations correlated with outcomes. Final analysis of PCYC-1121 demonstrated long-term safety and efficacy of ibrutinib in patients with relapsed/refractory MZL, regardless of prior treatment or MZL subtype. This trial was registered at www.clinicaltrials.gov as #NCT01980628.

31 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
JYJoachim Yahalom
Joachim Yahalom
AXAmy J. Xu
Amy J. Xu
ANAriela Noy
Ariela Noy
SLStephanie Lobaugh
Stephanie Lobaugh
MCMonica Chelius
Monica Chelius
ADAhmet Dogan
Ahmet Dogan
Treatment options for Helicobacter pylori–independent gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML) include surgery, immunotherapy, chemotherapy, and radiation therapy (RT). The purpose of this study was to investigate the efficacy and safety of RT and routine endoscopic surveillance, hypothesizing that most patients are curable with RT alone. We queried a single institution database at a tertiary referral cancer center for patients with H pylori–independent GML treated with RT between 1991 and 2017. Response was assessed by follow-up endoscopies (EGDs) starting 10 to 12 weeks post-RT. Computed tomography scans were also part of the follow-up program, and positron emission tomography was added when clinically appropriate. We identified 178 patients (median age, 63 years; range, 25-89 years); 86% had stage I disease, 7% had stage II disease, and 7% had stage IV disease. Median RT dose was 3000 cGy over 20 fractions. Ninety-five percent of patients exhibited complete pathologic response on posttreatment EGD. Two patients experienced grade 3 toxicity, and 2 patients experienced in-field secondary malignancies. Over a median follow-up of 6.2 years, 9.6% experienced local failures, and 11.8% developed distant sites of disease. Five-year and 10-year overall survival were 94% and 79%, respectively, from last date of RT. RT is a highly effective and safe treatment for GML with excellent overall survival and very rare acute or late treatment-related toxicities. Favorable outcomes from this large retrospective sample of patients provide credible and compelling support for RT as standard of care for H pylori–independent GML.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NFNathan Hale Fowler
Nathan Hale Fowler
MCMorton Coleman
Morton Coleman
DSDon A. Stevens
Don A. Stevens
SSSonali Smith
Sonali Smith
PVParameswaran Venugopal
Parameswaran Venugopal
BCBeth Christian
Beth Christian
7549Background: Bruton tyrosine kinase (BTK) inhibition has shown clinical benefit in FL. Acalabrutinib is a highly selective, potent, covalent inhibitor of BTK. We evaluated acalabrutinib ± R in a Phase 1b study of patients (pts) with treatment-naive (TN) or relapsed/refractory (R/R) FL. Methods: Pts with R/R FL (≥1 prior treatment) were randomized to acalabrutinib (mono) or acalabrutinib + R (combo); TN pts received the combo. In 28-day cycles, R (375 mg/m2 IV) was given weekly in Cycle 1 and on Day 1 of Cycles 2-6; acalabrutinib (100 mg PO bid [2 pts received 200 mg qd]) was given until progressive disease (PD) or intolerance. The primary endpoint was safety. Secondary endpoints included overall response rate (ORR), duration of response (DOR), pharmacokinetics (PK) and pharmacodynamics. Results: Thirteen TN and 27 R/R pts were treated. In all pts, the median age was 66 years (range 32-83), 98% of pts had ECOG PS ≤1, and 88% had stage III/IV disease. R/R pts received a median of 2 prior therapies (range...

16 November 2005 in Blood
Verified
Journal Article
Open access
FMFranck Morschhauser
Franck Morschhauser
JLJohn P. Leonard
John P. Leonard
BCBertrand Coiffier
Bertrand Coiffier
MPMarie-Odile Petillon
Marie-Odile Petillon
MCMorton Coleman
Morton Coleman
DGDavid M. Goldenberg
David M. Goldenberg
Background. Infusion reactions, prolonged infusion times and immunogenicity of the chimeric anti-CD20 antibody, rituximab, may in part be related to its murine component. The humanized anti-CD20 antibody, IMMU-106 (hA20), may offer potential advantages because only the CDRs are of murine origin and the remaining >90% human framework regions are identical to humanized anti-CD22 IgG1 antibody epratuzumab, whose safety and short infusion times have been reported. Methods. An open-label, multicenter, phase I/II, dose escalation study conducted in patients with recurrent B cell lymphoma to establish the safety, tolerance, pharmacokinetics, and immunogenicity of hA20 administered once weekly for 4 doses. Results. Twenty patients (11 M/9 F, 40–81 y.o) with grade 1–2 follicular (n=16) or other CD20+ B-cell lymphomas (mantle cell, small lymphocytic, marginal zone x 2) were enrolled in the dose escalation portion of this study, receiving 120 mg/m2 (n=7), 200 mg/m2 (n=6), 375 mg/m2 (n=4) or 750 mg/m2 (n=3) weekly x 4. These patients had previously received 1-7 prior therapies (median, 2.5), including treatments with one (n=12) or 2–4 (n=6) rituximab-containing regimens (without progression within 6 months). Five patients (25%) had grade 1–2 infusion reactions predominantly with first hA20 infusion. Median infusion times for 375 mg/m2 of hA20 were 3.3 hours for first infusion, 2.0 hours for subsequent infusions, and were generally shorter at lower doses. Standard laboratory values obtained at each infusion were generally observed to be within normal limits, and human anti-human antibody (HAHA) serum evaluations are negative to date. Peripheral blood B-cell depletion occurred after first infusion and persisted for samples obtained up to 12 weeks following fourth infusion with analysis ongoing. Pharmacokinetic results after first and fourth infusions demonstrate a mean antibody serum half-life of 5.3 ± 5.3 and 12.0 ± 8.7 days, respectively. To date, of 15 pts with at least one post-treatment assessments now completed, there are at least 8 objective responses (53%) by Cheson criteria, including 6 patients (40%) with complete responses [CR, CRu] at a median follow-up of 12 weeks. Complete responses have been observed at all dose levels, including 3/7 patients receiving 120 mg/m2/wk. Conclusion. This study demonstrates the safety, tolerability, and preliminary efficacy of this humanized anti-CD20 antibody administered weekly for 4 doses, mostly to patients with follicular lymphomas who relapsed after rituximab-containing regimens. The demonstration of CRs, tolerability, and relatively short infusion times is encouraging. This study is continuing and expanding to assess the durability of responses and the optimal dose for subsequent studies.

2 December 2016 in Blood
Verified
Journal Article
Open access
PFPeter A. Forsberg
Peter A. Forsberg
ARAdriana Rossi
Adriana Rossi
RPRoger N Pearse
Roger N Pearse
APArthur Perry
Arthur Perry
KPKaren Pekle
Karen Pekle
TMTomer M. Mark
Tomer M. Mark
Background- Currently combination regimens for induction therapy based around a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) or both are standard for the treatment of newly diagnosed multiple myeloma (NDMM). In phase II studies the combination of Carfilzomib, Lenalidomide and Dexamethasone (Dex) has led to very high rates of overall and deep responses as induction therapy (Jakubowiak Blood 2012). According to the Norton-Simon hypothesis, the sequential, dose-dense use of agents that are not cross-resistant and have minimal overlapping toxicity may eliminate the emergence of residual inherently resistant sub-clones which are responsible for relapse. A sequential approach may also allow for medications to be administered at higher doses and the incorporation of more active agents into an initial therapeutic platform than can be tolerated in a single combinatorial induction approach. To date limited research has been done which evaluates a planned sequential therapeutic protocol built around the successive administration of a highly active PI and IMiD for NDMM. We conducted a phase II study evaluating high dose Carfilzomib and Dex induction (Kd) followed by Lenalidomide, clarithromycin and Dex (BiRD) consolidation and Lenalidomide maintenance in NDMM to evaluate safety and efficacy of this approach Methods Between 2012 and 2015, 72 patients were enrolled in a phase II trial of the CarBiRD regimen for initial treatment of symptomatic NDMM. Patients received Carfilzomib intravenously over 30 minutes on days 1, 2, 8, 9, 15, 16 of a 28 day cycle with Dex 20mg orally on days of Carfilzomib therapy. Carfilzomib was administered at a dose of 20mg/m2 on days 1 and 2 of cycle one of therapy before escalation to target dosing on all subsequent treatment days. The initial protocol was designed with a target Carfilzomib dosing of 45mg/m2, following the enrollment of the first 26 patients on protocol the dosing was increased to 56mg/m2. After maximum response was achieved with Kd, defined as complete response or stable m-protein for 2 consecutive cycles, patients who were eligible for autologous stem cell transplant underwent stem cell collection. Patients then initiated consolidation with Lenalidomide, clarithromycin and Dex (BiRD). BiRD consisted of Lenalidomide 25mg daily on days 1-21 of 28 day cycles, with clarithromycin 500mg twice daily and Dex 40mg on days 1, 8, 15 and 22. BiRD was also continued until achievement of maximum response and patients subsequently initiated maintenance Lenalidomide (Len) at a dose of 10mg on 21 of 28 day cycles. Results 70 out off 72 patients completed at least one cycle of Kd and were evaluated for response. 15 patients came off trial during Carfilzomib therapy: 7 for toxicity, 2 for progression of disease and 6 for either withdrawal of consent, insurance issues or non-compliance. 3 patients came off trial during BiRD consolidation: 1 each for toxicity, progression of disease and withdrawal of consent. The remaining 57 patients initiated BiRD and 54 Len maintenance respectively. Responses are summarized in table 1. The overall response rate was 94% with 84% of patient's achieving a VGPR or better and 37% achieving CR or stringent CR. The rate of CR/sCR increased from 13% (9 of 70 patients) with Kd induction to 28% (16 of 57) with BiRD consolidation and 48% (26 of 54) with Len maintenance. 30% of patients (17 of 57) experience an increased depth of response by at least 1 IMWG response category during BiRD consolidation from their maximum response to Kd. 19% (10 of 54) had an increased depth of response category during Len maintenance. The large majority of adverse events were grade 1 or 2. The most common toxicities across protocol were low-grade gastrointestinal events. The most common grade 3 or higher toxicities were infectious with 17% of patients (12 of 72) experiencing at least one grade 3 or higher infection. Peripheral neuropathy developed in 31% of patients with no grade 3 or higher neuropathy emerging during treatment. The rate of emergent hematologic toxicities was very low across protocol. Discussion CarBiRD is an effective and well-tolerated treatment regimen for patients with NDMM. Using a sequential treatment approach with a highly effective PI and IMiD as the back bones of successive therapies led to high rates of overall response, VGPR or better and complete response in a deferred transplant and transplant ineligible setting.